At AAPS PharmSci 360 2025, held from Nov. 9–12 in San Antonio, Texas, Corey Bloom, PhD, associate director, CMC (chemistry, ...

Robust scale-down agitation models simulate mechanical stress essential for assessing and preventing protein aggregation in ...

To prevent catastrophic loss of expertise and investment, government and academic leaders say coordinated policy and significant investment in workforce talent are urgently needed in the UK.

The FDA's CNPV program accelerates product reviews to two months for national priority products, enhancing market entry speed ...

A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and ...

Frank Romanski of Lonza Capsugel dives into the excipient side of manufacturing and the emerging prevalence of digitalization.

3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

In the life sciences industry, the journey from discovery to delivery is only as strong as the supply chain and distribution ...

Ex vivo lung perfusion (EVLP) provides a platform for testing therapies but faces challenges in standardizing drug evaluation. At AAPS PharmSci 360, Xuanzi Zhou says digital twins accurately predict ...

Siddhant Sojitra, Alexion, defines in an AAPS PharmSci 360 2025 presentation an agitation model to reliably test stability for early-stage biologics.